Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Patrick Vallance appointed to GSK executive leadership team
GSK announced the appointment of Patrick Vallance, Medicines Discovery and Development and as a member of the Corporate Executive Team.
-
GSK extends presence in Asia with new strategic alliance in South Korea
GSK today entered into a strategic alliance with Dong-A, the number one pharmaceutical and OTC Company in South Korea.
-
GSK Statement on FDA Advisory Committee meeting on Rotavirus vaccines
GlaxoSmithKline (NYSE: GSK) today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting.
-
GSK announces Q1 results for 2010
GSK delivers Q1 EPS of 30.7p +16% CER before major restructuring
-
GlaxoSmithKline and Human Genome Sciences announce topline 76-week results of phase 3 trial of Benlysta™ in systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) and today announced topline secondary endpoints from BLISS-76.
-
GlaxoSmithKline receives conditional marketing authorisation in the EU for Arzerra® (ofatumumab)
GSK and Genmab AS confirmed that EC has granted a conditional marketing authorisation for Arzerra for the treatment of refractory CLL.
-
GSK and Isis Pharmaceuticals collaborate on RNA therapeutics for rare and infectious diseases
GSK has right to license and commercialise compounds at clinical proof-of-concept
-
GSK receives European approval for Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
-
GSK regulatory update – Avodart (dutasteride)
GSK announced today that it has re-submitted sNDA for Avodart (dutasteride) for prostate cancer risk reduction among men.
-
Updated GlaxoSmithKline statement on European regulatory guidance relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that the European Medicines Agency (EMA) has maintained its position.
-
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs.
-
GSK joins global vaccine alliance to help prevent millions of children from contracting pneumococcal disease in the world’s poorest countries
Unique finance mechanism ensures vaccinations will begin in 2010 - Up to 300 million doses to be supplied over ten years.
-
GSK announces succession plan for leadership of Consumer Healthcare business
Emma Walmsley appointed President, Consumer Healthcare Europe and President Designate, Worldwide Consumer Healthcare
-
GlaxoSmithKline statement on new information relating to manufacture of Rotarix (rotavirus vaccine)
GlaxoSmithKline (GSK) today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1.
-
GlaxoSmithKline announces Swiss approval of Duodart®
The first fixed dose combination medicine for benign prostatic hyperplasia
-
GlaxoSmithKline commences Relovair Phase III asthma programme
GlaxoSmithKline (GSK) announced today that the first asthma patient has commenced treatment with Relovair.
-
GSK publishes 2009 Corporate Responsibility Report
In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly.
-
GlaxoSmithKline receives marketing authorisation in the EU for Revolade® (eltrombopag)
GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted marketing authorisation for Revolade.
-
GSK commences succession plan for management of vaccines business
GlaxoSmithKline (GSK) today announced management changes related to its Vaccines business as part of a planned succession strategy.
-
GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF
(GSK) CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole.